StocksMedium•2 October 2026•
1 min read
Novartis Signs $7.8B RNA Therapeutics Deal with Abogen Biosciences
Key Facts
1Novartis signed a licensing and collaboration agreement with Abogen Biosciences to develop RNA-encoded therapeutics.
2The total potential value of the deal reaches up to $7.8 billion, including upfront payments and developmental milestones.
Novartis signed a licensing and collaboration agreement with Abogen Biosciences to develop RNA-encoded therapeutics. Reuters reported that the total potential value of the deal reaches up to $7.8 billion, including upfront payments and various developmental milestones.
The partnership aims to bolster the Novartis pipeline in the high-growth sector of RNA-encoded drug development. NVSEF closed at $140.93 on September 30, 2026, prior to the announcement of this strategic expansion into new therapeutic technologies.